(Reuters) -AbbVie ( ABBV ) said on Thursday its drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease.

The trial studied two doses of the drug, tavapadon, as a monotherapy in which patients showed a statistically significant improvement when compared to placebo, as measured on a rating scale that evaluates various aspects of the disease.

Tavapadon is being studied as a once-daily treatment for Parkinson's disease - a movement disorder of the nervous system which worsens over time.

AbbVie ( ABBV ) gained access to the treatment with its $8.7 billion buyout of Cerevel Therapeutics.

(Reporting by Sriparna Roy in Bengaluru; Editing by Anil D'Silva and Shailesh Kuber)